Cue Biopharma shares are trading higher. The company announced it will present new preclinical data for its lead autoimmune and inflammatory disease candidate, CUE-401, at IMMUNOLOGY2026.

Benzinga Newsdesk www.benzinga.com Neutral 53.1%

Neg 0% Neu 53.1% Pos 0%

Comments

No comments yet. Be the first!